Vanoxerine Mimics DC Cardioversion in Phase IIb Study

Chanrx Corp. moved a step closer to the goal line for lead candidate vanoxerine (GBR-12909), reporting Phase IIb data at the American Heart Association (AHA) 2013 Scientific Sessions suggesting the drug’s efficacy approached that of direct current (DC) cardioversion for patients with atrial fibrillation.